Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.

ABSTRACT:

Background

To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer.

Results

Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively.Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008).

Materials and methods

Three randomized phase III trials representing 1502 patients were identified.Pooled hazard ratio (HR), odd ratio (OR), risk ratio

SUBMITTER: Marchetti C 

PROVIDER: S-EPMC4914353 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature